# Supplemental materials: Table of contents

**Baseline kidney status classification schemes**

**Supplemental Table 1.** Chronic and total yearly eGFR slope in the overall population

**Supplemental Table 2.** Chronic and total yearly eGFR slope analyses by baseline kidney status

**References**

## Baseline kidney status classification schemes

1. Estimated glomerular filtration rate (eGFR) classification: Patients were classified into eGFR categories:

eGFR G1, if eGFR was ≥90 ml/min per 1.73 m2

eGFR G2, if eGFR was ≥60 and <90 ml/min per 1.73 m2

eGFR G3, if eGFR was <60 ml/min per 1.73 m2

2. Urinary albumin-to-creatinine ratio (UACR) classification: Patients were classified into:

Normoalbuminuria, if UACR was <30 mg/g

Microalbuminuria, if UACR was ≥30 and ≤300 mg/g

Macroalbuminuria, if UACR was >300 mg/g

3. The Kidney Disease: Improving Global Outcomes in Chronic Kidney Disease (KDIGO CKD) risk classification is based on the Kidney Disease: Improving Global Outcomes’ prognosis of CKD by eGFR and albuminuria categories (1). Patients were classified based on the risk for progression to CKD into:

Low risk, if baseline eGFR was ≥60 ml/min per 1.73 m2 and UACR <30 mg/g

Moderate risk, if baseline eGFR was ≥60 ml/min per 1.73 m2 and UACR ≥30 and ≤300 mg/g or if baseline eGFR was ≥45 and <60 ml/min per 1.73 m2 and UACR <30 mg/g

High/very high risk, if baseline eGFR was ≥60 ml/min per 1.73 m2 and UACR >300 mg/g or if baseline eGFR was ≥45 and <60 ml/min per 1.73 m2 and UACR >30 mg/g or if baseline eGFR was <45 ml/min per 1.73 m2.

Supplemental Table 1. Chronic and total yearly eGFR slope in the overall population.

|  |  |  |  |
| --- | --- | --- | --- |
| **Time Period** | **Treatment Group** | **Slope, ml/min per 1.73 m2 per year (least square mean [95% CI])** | **Difference Versus Placebo** |
| **least square mean (95% CI)** | ***P* valuea** |
| Weeks 6 to 104 | Placebo | −1.08 (−1.37, −0.79) | – | – |
| Ertugliflozin | 0.35 (0.14, 0.55) | 1.43 (1.07, 1.78) | <0.001 |
| Weeks 6 to 156 | Placebo | −1.51 (−1.70, −1.32) | – | – |
| Ertugliflozin | −0.32 (−0.45, −0.19) | 1.19 (0.95, 1.42) | <0.001 |
| Weeks 6 to 208 | Placebo | −1.45 (−1.60, −1.29) | – | – |
| Ertugliflozin | −0.42 (−0.52, −0.31) | 1.03 (0.84, 1.22) | <0.001 |
| Weeks 6 to 260 | Placebo | −1.51 (−1.66, −1.37) | – | – |
| Ertugliflozin | −0.49 (−0.59, −0.40) | 1.02 (0.84, 1.20) | <0.001 |
| Weeks 0 to 52 | Placebo | −0.22 (−0.68, 0.24) | – | – |
| Ertugliflozin | 0.67 (0.35, 1.00) | 0.89 (0.33, 1.46) | 0.002 |
| Weeks 0 to 104 | Placebo | −0.92 (−1.17, −0.67) | – | – |
| Ertugliflozin | 0.21 (0.03, 0.38) | 1.13 (0.83, 1.43) | <0.001 |
| Weeks 0 to 156 | Placebo | −1.35 (−1.52, −1.18) | – | – |
| Ertugliflozin | −0.29 (−0.41, −0.17) | 1.06 (0.85, 1.27) | <0.001 |
| Weeks 0 to 208 | Placebo | −1.34 (−1.48, −1.20) | – | – |
| Ertugliflozin | −0.38 (−0.48, −0.29) | 0.96 (0.79, 1.13) | <0.001 |
| Weeks 0 to 260 | Placebo | −1.41 (−1.54, −1.28) | – | – |
| Ertugliflozin | −0.45 (−0.54, −0.36) | 0.96 (0.80, 1.11) | <0.001 |

CI, confidence interval; eGFR, estimated glomerular filtration rate. Analysis performed on full analysis set. aTesting the difference between ertugliflozin and placebo groups.

Supplemental Table 2. Chronic and total yearly eGFR slope analyses by baseline kidney status.

|  |  |  |  |
| --- | --- | --- | --- |
|  | **eGFR G1(eGFR ≥90 ml/min per 1.73 m2)** | **eGFR G2(eGFR ≥60 and <90 ml/min per 1.73 m2)** | **eGFR G3eGFR <60 ml/min per 1.73 m2** |
| **Duration** | **Placebo** | **Ertugliflozin** | **Differencea** | **Placebo** | **Ertugliflozin** | **Differencea** | **Placebo** | **Ertugliflozin** | **Differencea** |
| **Weeks 6 to 104b** | −1.73 (−2.43, −1.03) | 0.16 (−0.33, 0.65) | 1.89 (1.03, 2.74) | −0.87 (−1.26, −0.49) | 0.42 (0.15, 0.68) | 1.29 (0.83, 1.76) | −0.78 (−1.29, −0.27) | 0.37 (0.01, 0.73) | 1.15 (0.53, 1.77) |
| **Weeks 6 to 156b** | −1.91 (−2.35, −1.47) | −0.72 (−1.03, −0.41) | 1.19 (0.65, 1.73) | −1.39 (−1.65, −1.14) | −0.18 (−0.35, −0.00) | 1.22 (0.91, 1.53) | −1.28 (−1.61, −0.96) | −0.22 (−0.45, 0.01) | 1.07 (0.66, 1.47) |
| **Weeks 6 to 208b** | −1.77 (−2.12, −1.42) | −0.83 (−1.07, −0.59) | 0.94 (0.52, 1.37) | −1.38 (−1.59, −1.17) | −0.28 (−0.43, −0.14) | 1.10 (0.84, 1.35) | −1.18 (−1.43, −0.93) | −0.27(−0.44, −0.10) | 0.91(0.61, 1.21) |
| **Weeks 6 to 260b** | −1.92 (−2.24, −1.59) | −0.92 (−1.15, −0.70) | 0.99 (0.60, 1.39) | −1.43 (−1.62, −1.23) | −0.36 (−0.49, −0.23) | 1.07 (0.84, 1.31) | −1.19 (−1.43, −0.95) | −0.32(−0.49, −0.16) | 0.86 (0.57, 1.16) |
| **Weeks 0 to 52****b** | −2.46 (−3.62, −1.30) | −0.97 (−1.79, −0.15) | 1.49 (0.07, 2.91) | −0.11 (−0.68, 0.46) | 0.91 (0.51, 1.31) | 1.02 (0.32, 1.71) | 2.18 (1.33, 3.02) | 2.05 (1.45, 2.65) | −0.13 (−1.16, 0.91) |
| **Weeks 0 to 104b** | −2.39 (−3.00, −1.80) | −0.73 (−1.16, −0.31) | 1.66 (0.93, 2.39) | −0.68 (−1.00, −0.36) | 0.40 (0.19, 0.62) | 1.08 (0.70, 1.47) | 0.28 (−0.16, 0.73) | 0.86(0.54, 1.17) | 0.57(0.03, 1.12) |
| **Weeks 0 to 156b** | −2.21 (−2.61, −1.81) | −1.05 (−1.33, −0.77) | 1.17 (0.68, 1.66) | −1.21 (−1.43, −0.98) | −0.09 (−0.24, 0.07) | 1.12 (0.85, 1.39) | −0.62 (−0.93, −0.32) | 0.13 (−0.08, 0.35) | 0.76(0.39, 1.13) |
| **Weeks 0 to 208b** | −2.02 (−2.33, −1.70) | −1.07 (−1.29, −0.85) | 0.95 (0.57, 1.34) | −1.24 (−1.43, −1.06) | −0.20 (−0.33, −0.07) | 1.05 (0.82, 1.27) | −0.70 (−0.91, −0.48) | 0.01 (−0.14, 0.16) | 0.71 (0.45, 0.97) |
| **Weeks 0 to 260b** | −2.11 (−2.41, −1.82) | −1.13 (−1.33, −0.92) | 0.99 (0.63, 1.34) | −1.30 (−1.48, −1.13) | −0.27 (−0.39, −0.16) | 1.03 (0.82, 1.24) | −0.74 (−0.94, −0.54) | −0.06 (−0.19, 0.08) | 0.69 (0.44, 0.93) |
|  | **Normoalbuminuria** | **Microalbuminuria** | **Macroalbuminuria** |
| **Duration** | **Placebo** | **Ertugliflozin** | **Differencea** | **Placebo** | **Ertugliflozin** | **Differencea** | **Placebo** | **Ertugliflozin** | **Differencea** |
| **Weeks 6 to 104b** | −0.74 (−1.12, −0.37) | 0.74 (0.48, 1.00) | 1.48(1.03, 1.94) | −1.12 (−1.66, −0.58) | −0.09 (−0.47, 0.29) | 1.03 (0.37, 1.69) | −3.48 (−4.53, −2.44) | −0.94 (−1.65, −0.23) | 2.54 (1.27, 3.81) |
| **Weeks 6 to 156b** | −1.16(−1.40, −0.92) | −0.04(−0.20, 0.13) | 1.13 (0.83, 1.42) | −1.77 (−2.12, −1.43) | −0.51 (−0.75, −0.27) | 1.26(0.84, 1.69) | −3.11 (−3.87, −2.36) | −1.56 (−2.07, −1.05) | 1.55 (0.64, 2.47) |
| **Weeks 6 to 208b** | −1.05(−1.25, −0.86) | −0.14(−0.28, −0.01) | 0.91 (0.67, 1.15) | −1.76 (−2.05, −1.47) | −0.59(−0.79, −0.39) | 1.17 (0.82, 1.52) | −3.27 (−3.85, −2.69) | −1.67 (−2.06, −1.28) | 1.60 (0.91, 2.30) |
| **Weeks 6 to 260b** | −1.13 (−1.31, −0.94) | −0.23(−0.35, −0.10) | 0.90(0.68, 1.12) | −1.84 (−2.11, −1.57) | −0.67 (−0.86, −0.49) | 1.16 (0.84, 1.49) | −3.32 (−3.87, −2.78) | −1.73 (−2.10, −1.36) | 1.59 (0.94, 2.25) |
| **Weeks 0 to 52b** | 0.09 (−0.50, 0.67) | 1.42(1.01, 1.84) | 1.34 (0.62, 2.06) | −0.27 (−1.13, 0.59) | 0.04 (−0.57, 0.66) | 0.31 (−0.75, 1.37) | −2.44 (−4.06, −0.81) | −2.06 (−3.17, −0.94) | 0.38 (−1.59, 2.35) |
| **Weeks 0 to 104b** | −0.56 (−0.88, −0.25) | 0.72(0.50, 0.94) | 1.28 (0.89, 1.67) | −0.98 (−1.43, −0.53) | −0.29 (−0.61, 0.03) | 0.69(0.14, 1.24) | −3.49 (−4.39, −2.60) | −1.60 (−2.21, −0.99) | 1.90 (0.81, 2.98) |
| **Weeks 0 to 156b** | −0.98 (−1.20, −0.77) | 0.07(−0.08, 0.22) | 1.06 (0.79, 1.32) | −1.60 (−1.91, −1.28) | −0.54 (−0.76, −0.32) | 1.06 (0.68, 1.45) | −3.20 (−3.87, −2.53) | −1.83 (−2.28, −1.38) | 1.37 (0.57, 2.18) |
| **Weeks 0 to 208b** | −0.94 (−1.12, −0.77) | −0.06(−0.18, 0.06) | 0.88 (0.68, 1.09) | −1.63 (−1.89, −1.37) | −0.60 (−0.78, −0.42) | 1.03 (0.72, 1.35) | −3.30 (−3.82, −2.79) | −1.84 (−2.19, −1.49) | 1.47 (0.84, 2.09) |
| **Weeks 0 to 260b** | −1.02 (−1.18, −0.86) | −0.14 (−0.25, −0.03) | 0.88 (0.68, 1.07) | −1.71 (−1.95, −1.47) | −0.67(−0.83, −0.50) | 1.04 (0.75, 1.33) | −3.34 (−3.83, −2.86) | −1.88(−2.21, −1.55) | 1.46 (0.88, 2.05) |
|  | **KDIGO CKD low risk** | **KDIGO CKD moderate risk** | **KDIGO CKD high/very high risk** |
| **Duration** | **Placebo** | **Ertugliflozin** | **Differencea** | **Placebo** | **Ertugliflozin** | **Differencea** | **Placebo** | **Ertugliflozin** | **Differencea** |
| **Weeks 6 to 104b** | −0.83 (−1.25, −0.40) | 0.69 (0.40, 0.99) | 1.52 (1.00, 2.04) | −1.04 (−1.57, −0.50) | 0.05 (−0.32, 0.42) | 1.09 (0.44, 1.74) | −1.92 (−2.56, −1.28) | −0.17 (−0.62, 0.28) | 1.75 (0.97, 2.53) |
| **Weeks 6 to 156b** | −1.26 (−1.54, −0.99) | −0.08 (−0.27, 0.11) | 1.18 (0.85, 1.52) | −1.58 (−1.92, −1.24) | −0.45 (−0.69, −0.22) | 1.13 (0.72, 1.54) | −2.13 (−2.58, −1.68) | −0.74 (−1.05, −0.43) | 1.39 (0.84, 1.93) |
| **Weeks 6 to 208b** | −1.14 (−1.36, −0.92) | −0.19 (−0.34, −0.04) | 0.95 (0.68, 1.22) | −1.57 (−1.85, −1.29) | −0.55 (−0.75, −0.36) | 1.01 (0.68, 1.35) | −2.16 (−2.52, −1.80) | −0.81 (−1.05, −0.56) | 1.35 (0.91, 1.79) |
| **Weeks 6 to 260b** | −1.21 (−1.42, −1.01) | −0.27 (−0.42, −0.13) | 0.94 (0.69, 1.19) | −1.67 (−1.92, −1.41) | −0.64 (−0.82, −0.47) | 1.02 (0.71, 1.33) | −2.16 (−2.50, −1.82) | −0.85 (−1.08, −0.61) | 1.32 (0.90, 1.73) |
| **Weeks 0 to 52b** | −0.56 (−1.22, 0.10) | 1.06 (0.59, 1.52) | 1.61 (0.81, 2.42) | −0.23 (−1.07, 0.61) | 0.57 (−0.02, 1.16) | 0.80 (−0.23, 1.82) | 0.54 (−0.45, 1.54) | −0.14 (−0.85, 0.57) | −0.69 (−1.91, 0.54) |
| **Weeks 0 to 104b** | −0.88 (−1.24, −0.53) | 0.54 (0.29, 0.79) | 1.42 (0.99, 1.86) | −0.89 (−1.35, −0.43) | −0.05 (−0.36, 0.27) | 0.84 (0.29, 1.40) | −1.21 (−1.76, −0.65) | −0.29 (−0.68, 0.10) | 0.91 (0.24, 1.59) |
| **Weeks 0 to 156b** | −1.20 (−1.45, −0.96) | −0.04 (−0.21, 0.13) | 1.17 (0.87, 1.47) | −1.43 (−1.74, −1.11) | −0.41 (−0.63, −0.19) | 1.02 (0.63, 1.40) | −1.69 (−2.10, −1.29) | −0.72 (−1.01, −0.44) | 0.97 (0.48, 1.47) |
| **Weeks 0 to 208b** | −1.12 (−1.32, −0.92) | −0.15 (−0.29, −0.02) | 0.97 (0.73, 1.21) | −1.46 (−1.71, −1.21) | −0.51 (−0.68, −0.34) | 0.95 (0.65, 1.26) | −1.80 (−2.13, −1.48) | −0.77 (−1.00, −0.55) | 1.03 (0.64, 1.43) |
| **Weeks 0 to 260b** | −1.19 (−1.37, −1.01) | −0.23 (−0.36, −0.11) | 0.96 (0.73, 1.18) | −1.56 (−1.79, −1.33) | −0.59 (−0.75. −0.43) | 0.97 (0.69, 1.25) | −1.83 (−2.14, −1.52) | −0.81 (−1.02, −0.60) | 1.02 (0.65, 1.39) |

CI, confidence interval; eGFR, estimated glomerular filtration rate; FAS, full analysis set; KDIGO CKD, Kidney Disease: Improving Global Outcomes in Chronic Kidney Disease. Analysis performed on full analysis set.
aDifference versus placebo (least square mean [95% CI]). beGFR slope (least square mean), ml/min per 1.73 m2 per year (95% CI).

# References

1. Work Group of Kidney Disease: Improving Global Outcomes (KDIGO): Chapter 1: Definition and classification of CKD. *Kidney Int Suppl* 3**:** 19-62, 2013